Neurofilament light chain: a biomarker for genetic frontotemporal dementia
Open Access
- 1 July 2016
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 3 (8), 623-636
- https://doi.org/10.1002/acn3.325
Abstract
Objective To evaluate cerebrospinal fluid (CSF) and serum neurofilament light chain (NfL) levels in genetic frontotemporal dementia (FTD) as a potential biomarker in the presymptomatic stage and during the conversion into the symptomatic stage. Additionally, to correlate NfL levels to clinical and neuroimaging parameters. Methods In this multicenter case–control study, we investigated CSF NfL in 174 subjects (48 controls, 40 presymptomatic carriers and 86 patients with microtubule‐associated protein tau (MAPT), progranulin (GRN), and chromosome 9 open reading frame 72 (C9orf72) mutations), and serum NfL in 118 subjects (39 controls, 44 presymptomatic carriers, 35 patients). In 55 subjects both CSF and serum was determined. In two subjects CSF was available before and after symptom onset (converters). Additionally, NfL levels were correlated with clinical parameters, survival, and regional brain atrophy. Results CSF NfL levels in patients (median 6762 pg/mL, interquartile range 3186–9309 pg/mL) were strongly elevated compared with presymptomatic carriers (804 pg/mL, 627–1173 pg/mL, P < 0.001), resulting in a good diagnostic performance to discriminate both groups. Serum NfL correlated highly with CSF NfL (rs = 0.87, P < 0.001) and was similarly elevated in patients. Longitudinal samples in the converters showed a three‐ to fourfold increase in CSF NfL after disease onset. Additionally, NfL levels in patients correlated with disease severity, brain atrophy, annualized brain atrophy rate and survival. Interpretation NfL in both serum and CSF has the potential to serve as a biomarker for clinical disease onset and has a prognostic value in genetic FTD.Keywords
Funding Information
- Medicinska Forskningsrådet
- Hjärnfonden
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Canadian Institutes of Health Research (AC14/00013, 20143810, 135043)
- Bundesministerium für Bildung und Forschung
- Alzheimer’s Research UK
- Brain Research Trust
- Wolfson Foundation (AC14/00013, 20143810, 135043)
This publication has 39 references indexed in Scilit:
- Geodesic Information Flows: Spatially-Variant Graphs and Their Application to Segmentation and FusionIEEE Transactions on Medical Imaging, 2015
- Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance imagesEuropean Journal of Neurology, 2015
- CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survivalNeurology, 2014
- Structural and functional brain connectivity in presymptomatic familial frontotemporal dementiaNeurology, 2014
- Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational dataThe Lancet Neurology, 2013
- Presymptomatic studies in ALSNeurology, 2012
- Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadicsBrain, 2012
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALSNeuron, 2011
- Classification of primary progressive aphasia and its variantsNeurology, 2011
- El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2000